Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
A Study to Asses the Effect of MK0663 in the Treatment of Patients With Postoperative Dental Pain (0663-092)
Phase 3
Completed
- Conditions
- Postoperative Dental Pain
- First Posted Date
- 2008-06-10
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 588
- Registration Number
- NCT00694369
A Study to Test the Effect of MK0217A on Vitamin D Inadequacy in Postmenopausal Women With Osteoporosis (0217A-262)
Phase 3
Completed
- Conditions
- Osteoporosis
- Interventions
- Drug: FOSAVANCE 5600 (Alendronate Sodium (+) cholecalciferol)Other: Referred-Care ModelDietary Supplement: Calcium Supplement 500 mg
- First Posted Date
- 2008-06-06
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 515
- Registration Number
- NCT00692913
Clinical Trial to Assess Efficacy, Safety, Treatment Adherence and Quality of Life Impact of Mometasone Furoate in Asthmatic Patients (Study P04879)(TERMINATED)
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 385
- Registration Number
- NCT00687531
Safety and Efficacy of Quadriderme® in the Treatment of Impetiginous Eczema (Study P05134AM4)
Phase 4
Terminated
- Conditions
- Eczema, AtopicSkin Diseases, EczematousDermatitis, Atopic
- Interventions
- Drug: Cream (betamethasone diproprionate, clotrimazole, and gentamicin sulfate)Drug: Cream (betamethasone diproprionate and gentamicin)Drug: Cream (betamethasone diproprionate)
- First Posted Date
- 2008-05-05
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 3
- Registration Number
- NCT00671528
Study of Inhaled Corticosteroid Plus Montelukast Compared With Inhaled Corticosteroid Therapy Alone in Patients With Chronic Asthma (0476-386)
Phase 2
Completed
- Conditions
- Asthma
- First Posted Date
- 2008-04-25
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 134
- Registration Number
- NCT00666679
Exercise Induced Bronchoconstriction (0476-359)
- First Posted Date
- 2008-04-23
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 24
- Registration Number
- NCT00664937
Begin With The Right Patients With Dual-Inhibition Action Therapy Through Vytorin for Newly Diagnosed Dyslipidemia Patients (0653A-172)(COMPLETED)
- First Posted Date
- 2008-04-08
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 173
- Registration Number
- NCT00654628
Coadministration of Ezetimibe and Simvastatin in Patients With Primary Hypercholesterolemia (P05457)
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 151
- Registration Number
- NCT00653523
Evaluation of Potential for Drug Interaction Between SCH 58235 (Ezetimibe) and Pitavastatin (Study P03962)(COMPLETED)
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 18
- Registration Number
- NCT00653913
Coadministration of Ezetimibe and Atorvastatin in Patients With Primary Hypercholesterolemia (P05456)
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 146
- Registration Number
- NCT00654095
© Copyright 2025. All Rights Reserved by MedPath